Inducing Broadly Neutralizing Antibodies to Protect Against HIV
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
AI97990A1 “Inducing Broadly Neutralizing Antibodies to Protect Against HIV” ABSTRACT Current HIV-1 vaccine strategies seek to engage naïve precursors of broadly neutralizing antibodies (bNAbs), such as the CD4-binding site (CD4bs) targeted ‘VRC01 class’ unmutated common ancestor (UCA), then drive its aKinity maturation toward breadth. In early studies, VRC01 UCAs did not bind to native HIV envelope glycoprotein (Env) trimers. However, a number of soluble Envs, including eOD-GT8, 426c gp120 core and BG505 SOSIP GT1.1 trimers were developed to successfully prime VRC01 class UCAs. These priming immunogens were engineered for increased sensitivity to VRC01-class UCAs. Changes include deletions of the N-linked potential glycosylation sites at Env position 276 (N276) and in the V5 loop, changes in loop D (Env positions 275-283), and/or other engineered changes to improve sensitivity. Boosting immunogens must be native or near native to be able to mature activated VRC01 class UCAs to become bNAbs. To date, no boosting immunogen has been able to successfully mature precursor ‘VRC01 class’ Abs toward bNAb status. Current boosting immunogens appear to lack the stringency needed to mature VRC01 activated UCAs fully accommodate the N276 glycan in functional Env trimers. A second limitation of current ‘VRC01 class’ bNAb lineage development strategies is that ‘oK-target’ epitopes on HIV-1 Env immunogens may dampen responses to desired sites. To address these challenges, we engineered native gp120/gp41 Env trimers to engage bNAb UCA B cells to induce the VRC01 lineage, thus increasing the possibility of maturing the UCAs to bNAb status with our cocktail of native trimer boosting immunogens. We will test our immunogens in appropriate animal models via delivery by nucleic acid in an authentic context to trigger and boost VRC01 UCAs to overcome the N276 glycan. Our Specific Aims are: 1. To express pure or nearly pure native membrane trimers that engage the VRC01 UCA. 2. To use native trimers to induce broad and potent bNAbs in VRC01 knock-in mice. 3. To define the maturation pathway of bNAbs elicited by native trimers in rhesus NHPs. We hypothesize that pure or nearly pure native trimer immunogens will provide the requisite stringency to stimulate VRC01 UCAs and guide them to become bNAbs. Our overall goal is to design and test a ‘native trimer’ prime-boost series to induce VRC01 class bNAbs. Our scientific premise is that native trimers, as the exclusive targets of NAbs provide an ideal format to induce NAbs.
Grant Summary
Inducing Broadly Neutralizing Antibodies to Protect Against HIV is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $809K for university, nonprofit, healthcare org. Applications are due 2027-05-31 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $809K
2027-05-31
- 1Confirm your organization is eligible for Inducing Broadly Neutralizing Antibodies to Protect Against HIV from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Inducing Broadly Neutralizing Antibodies to Protect Against HIV: Frequently Asked Questions
Who is eligible for the Inducing Broadly Neutralizing Antibodies to Protect Against HIV?
Inducing Broadly Neutralizing Antibodies to Protect Against HIV is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Inducing Broadly Neutralizing Antibodies to Protect Against HIV provide?
Inducing Broadly Neutralizing Antibodies to Protect Against HIV provides up to $809K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Inducing Broadly Neutralizing Antibodies to Protect Against HIV deadline?
Applications for Inducing Broadly Neutralizing Antibodies to Protect Against HIV are due 2027-05-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Inducing Broadly Neutralizing Antibodies to Protect Against HIV?
To apply for Inducing Broadly Neutralizing Antibodies to Protect Against HIV, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.